secwatch.observer — SEC 8-K summary
======================================

Issuer:     XBiotech Inc. (XBIT)
CIK:        0001626878
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001171843-24-000056
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XBiotech enters $10M convertible loan from CEO to fund new R&D facility
-----------------------------------------------------------------------

- $10M loan from CEO John Simard at 8% simple interest, secured by real estate and cash.
- Loan convertible to common stock at $4.048/share at CEO's election, subject to ownership cap.
- Interest-only payments semi-annually; CEO can demand cash repayment after one year.
- Funds will construct a 46,000+ sq ft R&D facility on 48-acre Austin campus; construction starts Q1 2024.
- New facility supports Natrunix rheumatology program and infectious disease research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626878/000117184324000056/0001171843-24-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626878/000117184324000056/f8k_010424.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer